|Bid||116.88 x 100|
|Ask||119.95 x 100|
|Day's Range||117.55 - 119.40|
|52 Week Range||71.46 - 121.96|
|PE Ratio (TTM)||165.41|
|Earnings Date||Jul 25, 2017 - Jul 31, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||124.52|
The key issue for the FTC is whether the deal kills competition between Concert's treatment and Vertex's Kalydeco.
Regeneron, Vertex and Alexion look likely to catch the next wave in biotech and start a boom, an analyst says.
Vertex Pharmaceuticals has launched a new college scholarship program for people affected by cystic fibrosis, the debilitating and often fatal lung disease that the Boston-based company has spent decades trying to tackle. Vertex (VRTX) said Friday it had awarded $5,000 each to 40 students nationwide — 26 cystic fibrosis patients and 14 immediate family members — for a total of $200,000. The scholarships will help to pay for two-year, four-year and graduate degrees.